© PHARMED CANADA

SPEAKERS 2019

Jean-Francois Pariseau

Unrepentant entrepreneur. Unrepentant investor. Co-founder of Amplitude. Led investments at BDC Capital’s Healthcare Fund and CDP Capital Technology Ventures. Lived the start-up dream, twice.

Lahav Gil

Lahav Gil is the CEO of RelayMedical, managing a portfolio of technologies and companies in the medtech, health IT and medications management marketplace. Lahav Founded/co-founded 6 companies. He has contributed to over 200 technology-product launches and several game-changing innovations for Canadian startups.

Maha Katabi

Maha joined Sofinnova as a Partner, where she focuses on development stage investments in therapeutics. Previously, Maha was a Managing Partner of Oxalis Capital, a Partner at Sectoral Asset Management and Vice-President at Ventures West Management, a venture capital firm focusing on technology and life sciences in Canada and the US.

Youssef Bennani

Dr. Youssef Bennani, Venture Partner of adMare BioInnovations is responsible for translating academic research into new companies of scale, to deploying a combination of physical infrastructure, scientific and business expertise, and capital, to help existing companies scale-up. Youssef also serves as the Chairman of the Board of Domain Therapeutics (France & Canada), and is an independent Board member of Bellus Health. 

RBC Ventures

Speaker to be confirmed

Anthony Ferrara

 

Anthony is the Associate Vice President, Commercial Banking Healthcare & Lifesciences for National Bank. Anthony covers Canada’s leading commercial banking team exclusively focused on high-growth opportunities in the Healthcare & Lifesciences space. The platform provides tailored solutions with respect to debt raises in M&A transactions, Healthcare & Lifesciences Private Equity and Sponsor coverage, growth and expansion capital structures, cash management, deposits and advisory services. 

Patrice Allibert

Dr Patrice Allibert is an accomplished business man, bringing a Molecular Diagnostic Company (GenePOC) from an early stage all the way to a liquidity event. Prior to this, he was Vice President R&D Molecular and Strategic Innovation for Molecular Infectious Diseases and he worked with Merial as Corporate Director for Bioanalytical Development.

Guy Barthell

Gur Barthell posesses over 30 years of experience in management and strategic consulting. He specializes in strategic planning, commercialization strategies, merger and acquisitions and due diligence. 

Louis Cossette

Trained as a scientist (Cellular and Molecular Biology), Louis  joined Deloitte to share his experience with companies who want to optimize their R&D using all the help available.